• Supporting Survivors

    Much of the progress in cancer treatment can be attributed to the recognition that not all cancers are the same. What if we took a similar approach to supporting survivors?

  • Living Through Pain

    Growing up, Beverly lived a very active life. Things changed when she got to college. Check out Chapter 2 of Beyond the Diagnosis to learn her story.

  • Beyond the Diagnosis

    Receiving a diagnosis is the first step in a longer journey. Over the next eight weeks, we'll explore that journey in a four-part, multimedia story.

Shuffle Most Popular Featured

Shutting Down Pain

Many pain medicines were discovered either by accident or by exploring traditional remedies; we're trying to understand the biology of pain using target-based drug discovery.

FDA Approval

On February 6, 2015, the FDA approved a Genentech Medicine for the treatment of diabetic retinopathy in people with diabetic macular edema (DME).

From Our Labs

Genentech scientists have found that a protein called DLK may play a role in many types of neurodegeneration, with implications for diseases like Alzheimer’s and ALS.

FDA Approval

On November 14, 2014, a Genentech medicine received FDA approval for use in a specific type of platinum-resistant ovarian cancer.

2014 ACR Annual Meeting

Presentations, Posters, and Papers galore. Check out our ACR 2014 newsroom to learn more about our commitment to rheumatology.

2014 AAO Annual Meeting

Genentech will present important new ophthalmic data at the 118th Annual Meeting of the American Academy of Ophthalmology (AAO) from October 18-21 in Chicago.

FDA Approval

On October 15, 2014, the FDA approved a medicine for the treatment of idiopathic pulmonary fibrosis (IPF).

Genentech Agrees to Acquire Seragon to Strengthen Breast Cancer Pipeline

Read about Genentech’s planned acquisition of Seragon.

New Insights on Breast Cancer Research

With the recent acquisition of Seragon, Genentech is excited to add a new class of investigational medicines known as SERDs to our pipeline.

Sunshine Act: Increasing Transparency

Genentech fully supports efforts to increase transparency around the partnership between the industry and healthcare professionals.

FDA Approval

Medicine for people with chronic idiopathic urticaria (CIU), a form of chronic hives.

Patient Access

Genentech is committed to ensuring price is not a barrier to access for patients. Learn about our programs.

Job Search

Search for jobs. Learn more about what is currently available. And then apply for the position at Genentech that’s right for you.

Genentech named FORTUNE Best Company

We're honored to earn a place on FORTUNE's "100 Best Companies to Work For" list for the 17th consecutive year.

Clinical Trial Data Sharing

As part of our commitment to sharing data from our clinical trials, researchers may request access to analyzable patient-level data. Learn more.